Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jalyn for BPH and CP/CPPS
NCT01830829Phase 3Terminated
- Start
- Apr 2013
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic prostatitis chronic pelvic pain syndrome (CP/CPPS) and benign prostatic hyperplasia (BPH) comparing Jalyn with Placebo (2 arms). Primary endpoint: National Institutes of Health Chronic Prostatitis Symptom Index at 6 months. Started Apr 2013; status: terminated.
02
Drugs
alpha blocker + 5-alpha reductase inhibitor
03
Conditions
chronic prostatitis chronic pelvic pain syndrome (CP/CPPS)benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT01830829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01830829.